Optimal deployment of limited vaccine supplies to combat mpox
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Mpox outbreaks in Central Africa have been declared a public health emergency of international concern by the World Health Organization. Fortunately, real-world effectiveness studies of the MVA-BN vaccine indicate that it has an effectiveness of 74% after one dose, and 82% after two doses against mpox. However, given the very limited supply of vaccines in Central Africa, there remain questions around the optimal deployment of limited MVA-BN doses. In this study, we consider whether more mpox cases might be averted by following the traditional two-dose vaccine regimen (4 week dosing interval), or by giving a single dose of MVA-BN to as many individuals as possible. We find that the optimal strategy depends on both, (i) the degree to which a subpopulation might be at higher risk of mpox, or severe mpox, infections, and (ii) how long ago the first dose was administered to the most at-risk subpopulation.
